ArticleFrontiers in endocrinology2026
An interpretable machine learning-based approach: development, validation, and clinical utility for distant metastasis prediction in PTC.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) constitutes 80-90% of all thyroid malignancies. Despite its generally favorable prognosis, 20-30% of PTC patients present intermediate/high-risk features, increasing distant metastasis risk. Traditional clinicopathological predictors (e.g., TNM stage, tumor size) have limited accuracy in forecasting metastasis, creating a need for more precise prediction tools.. Methods: A total of 2,452 PTC patients (diagnosed 2015-2023, follow-up ≥6 months) were enrolled, with data including clinical, pathological, laboratory, and ultrasound indices. Feature selection integrated LASSO, RFE, and ReliefF, identifying 7 core features. Nine machine learning (ML) algorithms were compared; SHAP analysis was used for interpretability. External validation included 432 patients, and a Django-based prediction website was developed.. Results: The LightGBM model exhibited optimal performance: test-set AUC = 0.886, accuracy = 0.887, and external validation AUC = 0.758. SHAP analysis identified extrathyroidal invasion (Mean |SHAP| = 0.1329) and thyroglobulin antibody (TgAb, Mean |SHAP| = 0.0981) as top predictors. Tumor size showed a nonlinear association with metastasis, and the model had a 93.6% negative predictive value (NPV) for excluding low-risk patients.. Conclusions: This interpretable ML model outperforms traditional predictors, effectively supporting clinical risk stratification and personalized treatment decision-making for PTC patients, with potential for broad clinical application..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.